Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature

Samplaski, Mary K.; Heston, Warren D.W.; Elson, Paul; Magi‐Galluzzi, Cristina; Hansel, Donna E.

doi:10.1038/modpathol.2011.112

Cited by 58 publications

(43 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSMA is a type II transmembrane protein that is over-expressed in PCa, including androgen-independent, advanced and metastatic disease [42–46] as well as in a few subtypes of bladder carcinoma [47], schwannoma [48], and in the tumor neovasculature of many solid tumors [49–52]. PSMA is also expressed on astrocytes where it is known as glutamate carboxypeptidase II (GCPII) and cleaves N -acetylaspartylglutamate (NAAG) into N -acetylaspartate (NAA) and glutamate [53, 54].…”

Section: Psma Biologymentioning

confidence: 99%

PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen

Mease

Foss²,

Pomper³

2013

CTMC

163

117

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second leading cause of cancer-related death in American men. Positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease, detection of metastatic lesions and, ultimately, for predicting the aggressiveness of disease. Prostate-specific membrane antigen (PSMA) is a well-characterized imaging biomarker of PCa. Because PSMA levels are directly related to androgen independence, metastasis and progression, PSMA could prove an important target for the development of new radiopharmaceuticals for PET. Preclinical data for new PSMA-based radiotracers are discussed and include new 89Zr- and 64Cu-labeled anti-PSMA antibodies and antibody fragments, 64Cu-labeled aptamers, and 11C-, 18F-, 68Ga-, 64Cu-, and 86Y-labeled low molecular weight inhibitors of PSMA. Several of these agents, namely 68Ga-HBED-CC conjugate 15, 18F-DCFBC 8, and BAY1075553 are particularly promising, each having detected sites of PCa in initial clinical studies. These early clinical results suggest that PET/CT using PSMA-targeted agents, especially with compounds of low molecular weight, will make valuable contributions to the management of PCa.

show abstract

Section: Psma Biologymentioning

confidence: 99%

PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen

Mease

Foss²,

Pomper³

2013

CTMC

163

117

View full text Add to dashboard Cite

show abstract

“…Interestingly, PSMA expression in the tumor neovasculature of some solid tumors (colon, breast, kidney, and subtypes of bladder cancer) poses potential pitfalls in imaging (32,(49)(50)(51)(52)(53)(54) but also offers potential opportunities for theranostic applications in cancers other than PC.…”

Section: Psma As Target For Pc Imaging and Therapymentioning

confidence: 99%

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

et al. 2017

View full text Add to dashboard Cite

The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over the last decade. Glu-ureabased PSMA ligands used for both imaging and radioligand therapy are the mainstays of the current success. For PET imaging, both 68 Gaand 18 F-labeled agents have been successfully translated to clinical applications. Mainly retrospective cohort studies have shown a high value in the setting of biochemical recurrence, with high detection rates even in the presence of low prostate-specific antigen levels. Preliminary data indicated that radioguided surgery with PSMA ligands may help to further improve patient outcomes because it facilitates the removal of small tumor deposits that are otherwise difficult to detect. For primary PC, PSMA ligand PET imaging has been shown to be superior to cross-sectional imaging for the detection of metastatic lymph nodes. In addition, it promises to also provide intraprostatic tumor localization, especially when used in combination with multiparametric MRI. Increasing numbers of studies have reported considerable changes in management resulting from PSMA ligand PET imaging for both biochemical recurrence and primary disease. The use of 177 Lu-PSMA-based radioligand therapy has demonstrated a reasonable response, mainly as defined by a prostate-specific antigen response of more than 50%, comparable to other recently introduced agents. Especially given the high level of safety of 177 Lu-PSMA radioligand therapy, with only minimal grade 3 and 4 toxicities reported so far, it has the potential to expand options for metastatic castrationresistant PC. This review is intended to provide a comprehensive overview of the current literature on low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on agents that have been clinically adopted.

show abstract

“…[8][9][10][11][12] The functional role of endothelial PSMA is not known and, as recent studies demonstrated, endothelial PSMA expression can vary significantly within and between different tumor types. [12][13][14] Cyclooxygenase 2 (COX2) is a key enzyme in the arachidonic acid metabolism involved in the biosynthesis of prostagladins, which contribute to a pro-angiogenic microenvironment in tumors. 15 Expression of COX2 is upregulated in squamous cell carcinoma and treatment with COX2 selective inhibitors results in reduced tumor growth.…”

mentioning

confidence: 99%

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

et al. 2012

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed in prostate cancer as well as in the neo-vasculature of nonprostatic solid tumors. Here, we determined the expression pattern of PSMA in the vasculature of oral squamous cell carcinoma. Using a previously validated antibody, PSMA staining distribution and cyclooxygenase 2 (COX2) expression status was evaluated in a cohort of patients with squamous cell carcinoma of the oral cavity (n ¼ 96) using immunohistochemistry and was correlated with clinicopathological features as well as outcome. Twenty-four (25%) cases showed no detectable PSMA staining, 48 (50%) demonstrated positive immunoreactivity for PSMA in less than 50% of microvessels and 24 (25%) cases showed strong endothelial PSMA expression in more than 50% of tumor-associated microvessels. High endothelial PSMA expression was associated with greatly reduced survival (18.2 vs 77.3 months; P ¼ 0.0001) and maintained prognostic significance after adjusting for grade and stage in multivariate analysis (hazard ratio ¼ 2.19, P ¼ 0.007). Furthermore, we observed a strong association between endothelial PSMA and cancer cell-specific COX2 expression. In conclusion, we provide the first evidence for the prognostic significance of endothelial PSMA expression in oral squamous cell carcinoma and, suggest a potential interaction between arachidonic acid metabolites and endothelial PSMA expression in the tumor neo-vasculature.

show abstract

Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature

Cited by 58 publications

References 17 publications

PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen

PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

Contact Info

Product

Resources

About